Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07502417 | A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants | PHASE1 | RECRUITING | 16 | — | — | Mar 27, 2026 | Jul 1, 2026 | Apr 28, 2026 | 1 | United States |
Cmax of Ethinyl Estradiol and Levonorgestrel.
Tmax of Ethinyl Estradiol and Levonorgestrel.
β of Ethinyl Estradiol and Levonorgestrel.
t1/2 of Ethinyl Estradiol and Levonorgestrel.
AUCt of Ethinyl Estradiol and Levonorgestrel.
AUCinf of Ethinyl Estradiol and Levonorgestrel.
An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
| Arm | Type | Description |
|---|---|---|
| Period 1 & 2 | EXPERIMENTAL | In Period 1, participants will receive a single dose of ethinyl estradiol and levonorgestrel. In Period 2, participants will receive multiple daily doses of ABBV-722 and a single dose of ethinyl estradiol and levonorgestrel. |
| Name | Type | Description |
|---|---|---|
| Ethinyl Estradiol + Levonorgestrel | DRUG | Oral |
| ABBV-722 | DRUG | Oral |
Inclusion Criteria: * Laboratory values meet the criteria specified in the protocol. * A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead electrocardiogram (ECG). Exclusion Criteria: * History of an...